Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073626 · ClinicalTrials.gov registry record · NA
Addressing Genomic Disparities in Cancer Survivors
A NA study of Genetic Testing and Hereditary Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 428
- Enrollment target
- 2
- Study locations
NCT06073626: Recruiting NA study of Genetic Testing and Hereditary Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT06073626 is a NA study of Genetic Testing and Hereditary Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 428 participants, below the 585-participant average among 7 other Genetic Testing trials with a reported enrollment target (27% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06073626, a NA study of Genetic Testing and Hereditary Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 428 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in genetic education and requests for genetic testing. 2. Evaluate the impact of the chatbot vs. EUC on the process that participants use to make decisions and evaluate effects on well-being (also called psychosocial outcomes). 3. Explore the ways (methods) that influence how participants experience the intervention. 4. Explore the feasibility of incorporating a Family Sharing Portal (FSP) for participants who receive a positive test result, to facilitate family communication of these test results and genetic testing of first-degree biological relatives after they have received genetic education by the RA. The main questions this study aims to answer are which group - the chatbot (RA) group or the EUC group - is more likely to request genetic testing and which group is more likely to get (engage with) genetic education. Participants will be randomly assigned to either the chatbot (RA) group or EUC group. This means each participant has an equal chance of being placed in either group, just like flipping a coin. Each group will receive genetic education and have an opportunity to request genetic testing. Researchers will compare the chatbot (RA) group and the EUC group to see which may request more GT (genetic testing) and which group engages more with genetic education.
Primary Outcome
As captured via internal RedCap form for the number or count of participants who opt for genetic testing, the investigators will test the efficacy of a culturally tailored and interactive electronic relational agent (RA) intervention vs. enhanced usual care (EUC) consisting of clinical letter and genetic recommendation on engagement in genetic testing uptake;
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Usual Care (EUC)
- BEHAVIORAL Relational agent (RA) / Chatbot
Study Locations (2)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
New Jersey
- Rutgers Cancer Institute - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 428 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2027-08-31 |
| Phase | NA |
What NCT06073626 shows while recruiting
NCT06073626 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 585-participant average among 7 other Genetic Testing trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Genetic Testing appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care (EUC) is the first listed.
NCT06073626 reports a single indexed study location in District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06073626 about?
NCT06073626 is a clinical study titled "Addressing Genomic Disparities in Cancer Survivors". The goal of this observational study is to increase genetic education and genetic testing for hereditary cancer risk among Black cancer survivors. The study will: 1. Test the effectiveness of a chatbot intervention (also called relational agent, or RA) vs. enhanced usual care (EUC) on engagement in...
What is the current status of trial NCT06073626?
This trial is currently recruiting. It is a NA study. The enrollment target is 428 participants. The study started on 2024-07-31. Estimated completion is 2027-08-31.
What conditions does trial NCT06073626 study?
This clinical trial studies the following conditions: Genetic Testing, Hereditary Cancer.
What interventions are being tested in trial NCT06073626?
The interventions under investigation include: Enhanced Usual Care (EUC) (BEHAVIORAL), Relational agent (RA) / Chatbot (BEHAVIORAL).
Who is sponsoring clinical trial NCT06073626?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073626 being conducted?
This trial has 2 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Genetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing Direct vs Indirect Methods for Cascade Screening
RECRUITING · NA
-
Universal Genetic Testing for Cancer Risk Reduction
RECRUITING · NA
-
Video Education With Result Dependent dIsclosure
RECRUITING · NA
-
Engaging Adolescents in Decisions About Return of Genomic Research Results
ACTIVE NOT RECRUITING · NA
-
Genetic Testing for All Breast Cancer Patients (GET FACTS)
ACTIVE NOT RECRUITING · NA
-
Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05566431 · 428 participants · NA
Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics
- NCT05646316 · 428 participants · Phase 3
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
- NCT05797610 · 428 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
- NCT06947538 · 428 participants · NA
Stepped Care for Posttraumatic Stress Disorder Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI